Cavalli F - Search Results

1

Mass spectrometric identification and analysis of some aphidicolin metabolites in cancer patients.

Davoli E, Zucchetti M, D'Incalci M, Sessa C, Cavalli F, Fanelli R. Davoli E, et al. Among authors: cavalli f. Biol Mass Spectrom. 1993 Jun;22(6):351-7. doi: 10.1002/bms.1200220607. Biol Mass Spectrom. 1993. PMID: 8329465

2

Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin.

Damia G, Tagliabue G, Zucchetti M, Davoli E, Sessa C, Cavalli F, D'Incalci M. Damia G, et al. Among authors: cavalli f. Cancer Chemother Pharmacol. 1992;30(6):459-64. doi: 10.1007/BF00685597. Cancer Chemother Pharmacol. 1992. PMID: 1394802

3

Phase I and clinical pharmacological evaluation of aphidicolin glycinate.

Sessa C, Zucchetti M, Davoli E, Califano R, Cavalli F, Frustaci S, Gumbrell L, Sulkes A, Winograd B, D'Incalci M. Sessa C, et al. Among authors: cavalli f. J Natl Cancer Inst. 1991 Aug 21;83(16):1160-4. doi: 10.1093/jnci/83.16.1160. J Natl Cancer Inst. 1991. PMID: 1886148 Clinical Trial.

4

Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients.

Zucchetti M, D'Incalci M, Willems Y, Cavalli F, Sessa C. Zucchetti M, et al. Among authors: cavalli f. Cancer Chemother Pharmacol. 1988;22(1):87-9. doi: 10.1007/BF00254189. Cancer Chemother Pharmacol. 1988. PMID: 3396150

5

A limited sampling model for the pharmacokinetics of etoposide given orally.

Gentili D, Zucchetti M, Torri V, Sessa C, de Jong J, Cavalli F, D'Incalci M. Gentili D, et al. Among authors: cavalli f. Cancer Chemother Pharmacol. 1993;32(6):482-6. doi: 10.1007/BF00685894. Cancer Chemother Pharmacol. 1993. PMID: 8258198

6

Low-dose oral etoposide in epithelial cancer of the ovary.

Marzola M, Zucchetti M, Colombo N, Sessa C, Pagani O, D'Incalci M, Cavalli F, Mangioni C. Marzola M, et al. Among authors: cavalli f. Ann Oncol. 1993 Jun;4(6):517-9. doi: 10.1093/oxfordjournals.annonc.a058565. Ann Oncol. 1993. PMID: 8353095 Free article.

7

Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.

Pagani O, Zucchetti M, Sessa C, de Jong J, D'Incalci M, De Fusco M, Kaeser-Fröhlich A, Hanauske A, Cavalli F. Pagani O, et al. Among authors: cavalli f. Cancer Chemother Pharmacol. 1996;38(6):541-7. doi: 10.1007/s002800050524. Cancer Chemother Pharmacol. 1996. PMID: 8823496 Clinical Trial.

8

Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717.

Sessa C, Zucchetti M, Ginier M, Willems Y, D'Incalci M, Cavalli F. Sessa C, et al. Among authors: cavalli f. Eur J Cancer Clin Oncol. 1988 Apr;24(4):769-75. doi: 10.1016/0277-5379(88)90313-6. Eur J Cancer Clin Oncol. 1988. PMID: 3383977

9

Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.

D'Incalci M, Rossi C, Zucchetti M, Urso R, Cavalli F, Mangioni C, Willems Y, Sessa C. D'Incalci M, et al. Among authors: cavalli f. Cancer Res. 1986 May;46(5):2566-71. Cancer Res. 1986. PMID: 3697995

10

Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results.

Sessa C, Zucchetti M, Torri V, Pagani O, D'Incalci M, Gentili D, Martinelli G, deJong J, Alerci M, Cavalli F. Sessa C, et al. Among authors: cavalli f. Ann Oncol. 1993 Aug;4(7):553-8. doi: 10.1093/oxfordjournals.annonc.a058587. Ann Oncol. 1993. PMID: 8395871 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

642 results

Search Page

Filters